• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

NEW DELHI: Morepen Laboratories Ltd has filed a patent for a new polymorphic Form IV of cholesterol lowering drug, Atorvastatin Calcium, in about 33 countries, including the US, Canada and other European countries.

According to a company statement, Morepen received approval for Atorvastatin under the Patent Co-operation Treaty last year. Currently, the market for this drug is $10 billion and the company is in the process of finalising tie-ups with other generic companies in the US to market the drug there. It hopes to capture 15-20 per cent of the market.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
GAIL to buy bottling units from pvt LPG cos

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line